** Shares of cancer therapy developer Greenwich LifeSciences GLSI.O rise 18.8% to $11 premarket
** GLSI says its experimental therapy, GLSI-100, to prevent breast cancer recurrences showed an increased immune response over time in patients during a late-stage study
** The therapy creates an immune response over time, as measured by the increasing injection site reactions with increased vaccinations
** Company says in the preliminary data, the patients reported immune response increased over time from baseline through the 4th- to 6th-month vaccinations
** As of last close, stock has fallen 51.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。